Lmcg Investments LLC Increases Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Lmcg Investments LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 103,025 shares of the biopharmaceutical company’s stock after acquiring an additional 650 shares during the quarter. Lmcg Investments LLC’s holdings in Gilead Sciences were worth $9,516,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. State Street Corp boosted its stake in shares of Gilead Sciences by 1.4% in the third quarter. State Street Corp now owns 60,171,691 shares of the biopharmaceutical company’s stock valued at $5,044,795,000 after purchasing an additional 841,776 shares during the period. Wellington Management Group LLP grew its stake in shares of Gilead Sciences by 50.9% during the third quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock valued at $2,900,921,000 after acquiring an additional 11,665,593 shares in the last quarter. FMR LLC lifted its stake in shares of Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock worth $2,780,329,000 after acquiring an additional 14,680,161 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Gilead Sciences by 2.1% in the third quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock valued at $2,302,119,000 after purchasing an additional 574,421 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in Gilead Sciences by 0.8% during the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company’s stock worth $851,743,000 after purchasing an additional 93,068 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 456,234 shares of company stock worth $42,130,461. 0.29% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on GILD. Leerink Partnrs raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. UBS Group boosted their price objective on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Bank of America reaffirmed a “buy” rating and set a $109.00 target price on shares of Gilead Sciences in a report on Tuesday, December 10th. Piper Sandler boosted their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Trading Up 0.2 %

Gilead Sciences stock opened at $91.84 on Tuesday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The firm has a market capitalization of $114.46 billion, a PE ratio of 1,020.44, a PEG ratio of 1.29 and a beta of 0.18. The business’s 50-day simple moving average is $91.75 and its 200-day simple moving average is $84.20.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the company earned $2.29 earnings per share. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. Equities research analysts forecast that Gilead Sciences, Inc. will post 4.36 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were issued a $0.77 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.35%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.